Jun. 30 at 11:45 PM
$NSPR $NSPR
FDA ✅
Russell Index ✅
Disruptive stroke-prevention tech ✅
Market cap? Just
$80M.
Stock price?
$2.20.
Where should we be?
$10. At least.
Let’s be honest:
This company has the technology to justify a
$300M–
$500M market cap.
The only thing holding it back is management’s inability to protect shareholder value. Dilution after dilution, reverse splits, and zero proactive IR. The market doesn’t trust them — and with good reason.
We’re not here because of fundamentals.
We’re here because of broken execution and broken promises.
With proper strategy and alignment, this stock should be trading at
$8–
$12, easy.
Don’t let this FDA approval be wasted.
We believed in the tech. Now it’s time for management to prove they believe in the shareholders.
They’ve failed in their fiduciary duty.
Retail investors deserve better.
Shall we go to the SEC?
#NSPR #FiduciaryDuty #SECWatch #ShareholderRights #RetailDeservesRespect #NSPR #FDA #ValueDestruction #FiduciaryDuty #RetailDeservesBetter
